160 results
Page 4 of 8
8-K
EX-10.1
qonln lbxz4m1i9i7z
26 Apr 22
Departure of Directors or Certain Officers
6:51am
8-K
EX-2.1
yy73gk408fl
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
424B5
9wb92a
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-10.1
5h1pu82b7y2fgwc282fb
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-4.2
mebxucqf8d
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-4.1
uwvmf8 bz
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am